8-K: Rezolute's sunRIZE Misses Endpoints, Tumor HI EAP Shows Promise

Rezolute, Inc. announced that its Phase 3 sunRIZE study for congenital hyperinsulinism did not meet primary or key secondary endpoints, while its Expanded Access Program for tumor hyperinsulinism showed compelling evidence of ersodetug activity.

Summary

• The Phase 3 sunRIZE study for congenital hyperinsulinism (HI) did not meet its primary (hypoglycemia events) or key secondary (time in hypoglycemia) endpoints.
• Despite missing endpoints, the company believes ersodetug shows pharmacologic activity, with target therapeutic drug concentrations achieved and highly sensitive biomarker responses (increases in circulating insulin) consistent with previous Phase 2 data.
• A significant placebo response was observed in sunRIZE, attributed to intensive monitoring and frequent clinical interactions in an ambulatory setting.
• All 59 participants who completed the sunRIZE study elected to continue in the open-label extension (OLE), with 57 remaining, some now on ersodetug as monotherapy.
• In the Expanded Access Program (EAP) for tumor HI, ersodetug was provided to over a dozen patients, showing substantial improvement in hypoglycemia and leading to a reduction or complete discontinuation of IV glucose infusion.
• 75% of EAP patients receiving IV dextrose/total parental nutrition (TPN) achieved complete discontinuation of IV dextrose/TPN.
• The Phase 3 upLIFT study for tumor HI is now a single-arm, open-label study, with topline results anticipated in the second half of 2026.
• The company has $152 million in cash, providing a runway to mid-2027.
• The estimated total global market opportunity for ersodetug is over $1 billion, with an initial U.S. addressable market of approximately 4,500 patients across congenital HI, malignant insulinoma, and non-islet cell tumor HI.

Sentiment

Score: 4

Explanation: The failure of the sunRIZE study to meet its primary endpoints is a significant negative, tempered by positive data from the tumor HI EAP and the high retention in the sunRIZE OLE, suggesting some underlying drug activity. The company's strong cash position provides stability, but the path forward for congenital HI is now uncertain and dependent on FDA discussions.

Positives

• Ersodetug demonstrated pharmacologic activity in the sunRIZE study, with target therapeutic drug concentrations achieved and biomarker responses (increased circulating insulin) consistent with Phase 2 data.
• All 59 participants who completed the sunRIZE study elected to continue in the open-label extension (OLE), indicating perceived benefit, with 57 participants still enrolled.
• Several children in the OLE have been able to stop all other therapies and are now receiving ersodetug as monotherapy.
• The Expanded Access Program (EAP) for tumor HI showed compelling evidence of ersodetug activity, with 75% of patients on IV dextrose/TPN achieving complete discontinuation.
• Ersodetug in the EAP was generally well-tolerated and led to substantial improvement in hypoglycemia, reduced glucose infusion rates, and hospital discharges.
• The company is well-capitalized with $152 million in cash, providing a runway to mid-2027.
• The total global market opportunity for ersodetug is estimated to be over $1 billion.
• The Phase 3 upLIFT study for tumor HI has been revised to a single-arm, open-label study, potentially streamlining the path to approval.

Negatives

• The Phase 3 sunRIZE study for congenital hyperinsulinism did not meet its primary endpoint (hypoglycemia events) or key secondary endpoint (time in hypoglycemia).
• The lack of statistical significance in sunRIZE was partly attributed to a "pronounced study effect" in the placebo arm, where intensive monitoring and frequent clinical interactions independently influenced outcomes.

Risks

• The sunRIZE study did not meet its primary or key secondary endpoints, which could impact the regulatory path for ersodetug in congenital HI.
• There is inherent uncertainty in predicting clinical trial results or the actual effects of plans or strategies.
• The possibility of the FDA not agreeing to a streamlined path for advancing the congenital HI program, despite the lack of statistical significance in sunRIZE.
• Actual results may differ materially from anticipated results, as discussed in SEC filings, including Risk Factors in Form 10-K and 10-Q.
• The challenge of studying glucose in an ambulatory setting, where factors like intensive monitoring and frequent clinical interactions can independently influence outcomes, as observed in the sunRIZE placebo arm.

Future Outlook

The company plans to engage with the FDA in Q1 2026 under its Breakthrough Therapy Designation to discuss the full sunRIZE dataset and explore options for the congenital hyperinsulinism indication. Topline results for the Phase 3 upLIFT study in tumor hyperinsulinism are anticipated in the second half of 2026. The company projects its current cash of $152 million will provide a runway to mid-2027.

Management Comments

• Company believes that data from sunRIZE and the Expanded Access Program (EAP) provide evidence of activity of ersodetug in both indications.
• Company plans to meet with FDA to align on path forward for congenital HI.
• The Company believes that the extent of reduction from baseline in hypoglycemia events and time in hypoglycemia relative to placebo may have been impacted by the prolonged treatment duration of six months and the fact that glucose monitoring is necessary for safe patient management while also serving as the key endpoint in the study.
• The Company believes that a potential indicator of ersodetugs underlying efficacy is that several children in the OLE have been able to stop taking all other therapies and are now receiving ersodetug as monotherapy.

Industry Context

Rezolute's ersodetug targets hyperinsulinism, a rare disease with significant unmet medical needs, particularly for congenital HI where 60% of patients do not respond to the only approved medication, Diazoxide, and for tumor HI where treatment options are limited and often ineffective. The company's approach with a fully human monoclonal antibody that acts downstream from the pancreas offers a potentially universal treatment for all forms of HI, differentiating it from existing therapies that often have suboptimal efficacy or serious side effects. The high placebo response observed in sunRIZE highlights the challenges of clinical trials in ambulatory settings for glycemic control, a common issue in diabetes and hypoglycemia research.

Comparison to Industry Standards

• Diazoxide (DZ) is the first-line treatment and only approved medication for hypoglycemia caused by HI, but 60% of patients do not respond, and it has frequent and serious adverse reactions including volume overload, heart failure, and pulmonary hypertension. Ersodetug aims to address this significant unmet need.
• Other available treatment options like Glucagon (temporizing, short-term) and Somatostatin analogs (marginal efficacy, serious pediatric side effects) are suboptimal compared to the potential broad efficacy of ersodetug.
• Pancreatectomy, an invasive option for DZ non-responsive patients, frequently requires adjuvant medications and can lead to insulin-dependent diabetes, making a non-surgical option like ersodetug highly desirable.
• In tumor HI, tumor-directed therapies do not directly treat hypoglycemia, and existing therapies like Diazoxide, Somatostatin analogs, and mTOR-inhibitors are often ineffective or poorly tolerated, especially in non-islet cell tumors where HI is caused by non-insulin substances like IGF-2. Ersodetug's mechanism of action directly addresses the over-activation of the insulin receptor, offering a novel approach.
• Compared to other therapies in development like Dasiglucagon (Zealand) and Avexitide (Amylyx), ersodetug's mechanism as an insulin receptor allosteric modulator and its utility in chronic use for congenital and tumor HI appear distinct, with some competitors not pursuing congenital HI or having earlier development stages.

Stakeholder Impact

• Shareholders: Potential negative impact due to the sunRIZE study's failure to meet endpoints, offset by positive EAP data and strong cash position. Future share price will depend on FDA discussions and upLIFT results.
• Patients (Congenital HI): Continued hope for an effective treatment, especially for those in the OLE showing benefit, but regulatory uncertainty remains.
• Patients (Tumor HI): Positive outlook given the strong EAP results and the progression of the upLIFT study, offering a potential new treatment option for severe hypoglycemia.
• Employees: Continued focus on advancing ersodetug, with the company's financial stability providing job security through mid-2027.
• Regulatory Authorities (FDA): Will be engaged in discussions regarding the sunRIZE data and the path forward for ersodetug in congenital HI.

Next Steps

• Meet with the FDA in Q1 2026 under Breakthrough Therapy Designation to discuss the full sunRIZE dataset and explore options for the congenital HI indication.
• Continue the open-label extension (OLE) portion of the sunRIZE study to assess potential benefit.
• Anticipate topline results for the Phase 3 upLIFT study in tumor HI in the second half of 2026.
• Evaluate patient-reported quality of life outcomes from the sunRIZE study.

Key Dates

Recommendation

The sunRIZE study's failure to meet its primary endpoints for congenital hyperinsulinism is a significant setback, introducing regulatory uncertainty for this indication. However, the strong positive data from the Expanded Access Program for tumor hyperinsulinism and the high retention rate in the sunRIZE open-label extension provide a counterbalance, suggesting ersodetug's potential efficacy in other HI forms or in a real-world setting. The company's solid cash position ($152 million with runway to mid-2027) provides financial stability to pursue its next steps, including critical FDA discussions in Q1 2026 and the anticipated upLIFT topline results in 2H 2026. Given the mixed results and upcoming catalysts, a 'hold' recommendation is appropriate, awaiting further clarity on the regulatory path for congenital HI and the definitive results from the upLIFT study before making a more decisive investment move.

Keywords

Rezolute, RZLT, Ersodetug, Hyperinsulinism, Congenital Hyperinsulinism, Tumor Hyperinsulinism, Hypoglycemia, sunRIZE study, upLIFT study, Expanded Access Program, Rare Disease, Clinical Trial, Phase 3, FDA, Breakthrough Therapy Designation, Insulinoma, Neuroendocrine Tumors, Monoclonal Antibody, Biotechnology, Pharmaceuticals